9SO Stock Overview
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Solasia Pharma K.K. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.13 |
| 52 Week High | JP¥0.42 |
| 52 Week Low | JP¥0.13 |
| Beta | 1.23 |
| 1 Month Change | -25.57% |
| 3 Month Change | -48.83% |
| 1 Year Change | -55.14% |
| 3 Year Change | -87.64% |
| 5 Year Change | -90.77% |
| Change since IPO | -94.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9SO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -3.1% | 1.8% |
| 1Y | -55.1% | -22.4% | 2.2% |
Return vs Industry: 9SO underperformed the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: 9SO underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 9SO volatility | |
|---|---|
| 9SO Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9SO's share price has been volatile over the past 3 months.
Volatility Over Time: 9SO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 24 | Yoshihiro Arai | www.solasia.co.jp |
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers episil oral liquid for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; Sancuso, a transdermal delivery system that delivers granisetron, an anti-emetic into the patient’s bloodstream for the treatment of chemotherapy induced nausea and vomiting; and Darvias injection, and antineoplastic agent/organic arsenic product indicated for relapsed or refractory peripheral T-cell lymphoma. It is also involved in the development of SP-04, a chemotherapy induced peripheral neuropathy which is in pre-clinical stage.
Solasia Pharma K.K. Fundamentals Summary
| 9SO fundamental statistics | |
|---|---|
| Market cap | €26.24m |
| Earnings (TTM) | -€6.71m |
| Revenue (TTM) | €3.72m |
7.0x
P/S Ratio-3.9x
P/E RatioIs 9SO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9SO income statement (TTM) | |
|---|---|
| Revenue | JP¥617.00m |
| Cost of Revenue | JP¥280.00m |
| Gross Profit | JP¥337.00m |
| Other Expenses | JP¥1.45b |
| Earnings | -JP¥1.11b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -6.39 |
| Gross Margin | 54.62% |
| Net Profit Margin | -180.23% |
| Debt/Equity Ratio | 0% |
How did 9SO perform over the long term?
See historical performance and comparison